ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $14,208,000 | +221.9% | 265,772 | +148.4% | 0.12% | +125.5% |
| Q3 2020 | $4,414,000 | +7.3% | 107,000 | +11.3% | 0.06% | -6.8% |
| Q4 2019 | $4,113,000 | +18.9% | 96,143 | 0.0% | 0.06% | -10.6% |
| Q3 2019 | $3,460,000 | +27.0% | 96,143 | -5.6% | 0.07% | +57.1% |
| Q2 2019 | $2,724,000 | -95.8% | 101,900 | -97.6% | 0.04% | -94.6% |
| Q2 2018 | $65,392,000 | -12.9% | 4,282,400 | +28.2% | 0.78% | -16.2% |
| Q1 2018 | $75,066,000 | +193.6% | 3,340,700 | +293.4% | 0.93% | +188.2% |
| Q4 2017 | $25,566,000 | -36.4% | 849,100 | -27.4% | 0.32% | -29.2% |
| Q1 2017 | $40,190,000 | +2.6% | 1,169,000 | -16.6% | 0.46% | +10.7% |
| Q1 2016 | $39,189,000 | +1061.5% | 1,401,600 | +938.2% | 0.41% | +724.0% |
| Q4 2013 | $3,374,000 | -60.6% | 135,000 | -56.7% | 0.05% | -67.3% |
| Q3 2013 | $8,571,000 | -63.5% | 312,000 | -75.9% | 0.15% | -69.2% |
| Q2 2013 | $23,468,000 | – | 1,293,000 | – | 0.50% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |